• Yanju Bao, Wei Hou, Liping Yang, Xiangying Kong, Maobo Du, Honggang Zheng, Yebo Gao, and Baojin Hua.
• From the Departments of *Oncology and †Nephrology, Guang'anmen Hospital, ‡Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, and §Beijing University of Chinese Medicine, Beijing, China.
• Reg Anesth Pain Med. 2015 Mar 1;40(2):158-65.

Background And ObjectivesBone cancer pain affects the quality of life of cancer patients. This study was aimed at investigating the analgesic effects of combined therapies with an antagonist of proteinase-activated receptor (PAR) 2 and morphine on pain-related behaviors in a rat model of bone cancer pain.MethodsFemale Wistar rats were inoculated intramedullarily with Walker 256 cells into their tibias. The analgesic effects of intraperitoneal treatment with morphine and/or intrathecal with the PAR2 antagonist, FSLLRY-NH2, on bone cancer pain-related behaviors in rats were examined.ResultsTreatment with morphine at 3 or 10 mg/kg significantly improved limb-use and weight-bearing scores and reduced the number of spontaneous flinches in rats. Treatment with FSLLRY-NH2 at 10 mmol/L also significantly improved limb use and weight bearing scores, and reduced the number of spontaneous flinches in rats. Combination a sub-analgesic dose of FSLLRY-NH2 (0.1 mmol/L) and morphine further elevated limb-use and weight-bearing scores and reduced the number of flinches compared with the effects of morphine alone in rats.ConclusionsOur data indicate that the combination of morphine and FSLLRY-NH2 has potent analgesic effects on bone cancer pain and our findings may aid in design of new strategies for the treatment of bone cancer pain.

37 keywords...

hide…